AXA Framlington Biotech GBP Z Acc (FUND:B784NS1) - Fund price

Fund Report

AXA Framlington Biotech Fund GBP Z Acc

Key Stats
Morningstar® CategorySector Equity Biotechnology
Manager NameLinden Thomson
Inception Date16/04/2012
NAV 22/01/2021GBX 496.90
Day Change-0.58%
12 Month Yield0.00%
Dividend FrequencySemi-Annually
Net Assets (mil) 31/12/2020513.05 GBP
Wrapper AvailabilityAll
Our Minimum Initial Investment1.00 Share
Pricing FrequencyDaily
Dealing Cut off Time10:45:00
Regular InvestmentYes
Actual Initial Charge0.00%
Exit Charge-
Custody ChargeYes
Ongoing Cost0.83%
Fund Rebate-

Morningstar Rating™

4 Stars

Morningstar® Sustainability Rating



Sustainability Rating as of 30/11/2020


Fund Benchmark

NASDAQ Biotechnology TR USD

Morningstar® Benchmark

NASDAQ Biotechnology TR USD

Growth Of 10,000 (GBP) 31/12/2020

How has this security performed
  • Fund: AXA Framlington Biotech Fund GBP Z Acc
  • Category: Sector Equity Biotechnology
  • Benchmark: NASDAQ Biotechnology TR USD
Trailing Returns % (GBP) 22/01/2021
3 Years Annualised14.6313.2814.34
5 Years Annualised14.1313.4513.19
10 Years Annualised19.7617.8720.33

Morningstar SRRI

Lower Risk
Higher Risk
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Potentially Lower ReturnsPotentially Higher Returns
Source: Morningstar

Investment Objective

The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Fund may also invest in other transferable securities and units in collective investment schemes. The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.

Portfolio Profile31/12/2020

Morningstar Style Box®

Equity Style

Large, Mid, SmallSize
Value, Blend, Growth
Top Holdings
IncreaseDecreaseNew since last portfolio
Amgen Inc Healthcare6.32
Alexion Pharmaceuticals Inc Healthcare6.20
Regeneron Pharmaceuticals Inc Healthcare5.51
Vertex Pharmaceuticals Inc Healthcare4.19
IncreaseSeagen Inc Ordinary Shares Healthcare3.92
Asset Allocation %
Top Stock Regions
United States87.70
Asia - Emerging3.46
United Kingdom2.04
Europe - ex Euro1.99
Top Stock Sectors
Stock Sector%
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.